載入中
NASDAQHealthcareMedical - Pharmaceuticals
最新資料
US$3.24
−US$0.67 · -17.14%
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
收盤時
US$3.24
−US$0.67 · -17.14%
盤後
US$3.47
+US$0.23 · +7.10%
10月13日 下午4:13 ET
盤中時間採用ET。市場資料可能有所延遲。
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
日內區間
目前US$3.24
52週區間
目前US$3.24
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
10
估值過高
情緒
58
多空交錯
風險
91
極高風險
動能
35
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
日內區間
目前US$3.24
52週區間
目前US$3.24
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 43.16萬 USD | 13.66萬 USD | 136.38萬 USD | 1025.02萬 USD | 988.94萬 USD |
| 銷貨成本 | 10.01萬 USD | 13.06萬 USD | 131.48萬 USD | 473.09萬 USD | 514.35萬 USD |
| 毛利 | 33.15萬 USD | 6005 USD | 4.9萬 USD | 551.93萬 USD | 474.6萬 USD |
| 研究與開發 | 195.63萬 USD | 223.67萬 USD | 10.03萬 USD | 99.32萬 USD | 89.97萬 USD |
| 銷售、一般及管理費用 | 1452.27萬 USD | 1205.4萬 USD | 444.55萬 USD | 656.68萬 USD | 753.58萬 USD |
| 營業費用 | 1657.63萬 USD | 1470.7萬 USD | 444.55萬 USD | 843.52萬 USD | 1003.83萬 USD |
| 利息收入 | 30.27萬 USD | 13.53萬 USD | 4198 USD | 2.1萬 USD | — |
| 利息支出 | 408.32萬 USD | 133.56萬 USD | 114.32萬 USD | 33.62萬 USD | 2.36萬 USD |
| 折舊和攤銷 | 49.18萬 USD | 5.34萬 USD | 104.98萬 USD | 19.47萬 USD | 13.89萬 USD |
| 營業利益 | −1624.48萬 USD | −1470.1萬 USD | −439.65萬 USD | −291.6萬 USD | −529.23萬 USD |
| 淨利 | −4151.23萬 USD | 906.58萬 USD | −1784.36萬 USD | −347.21萬 USD | −531.59萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2024年7月19日 | US$1.50Special | 2024年7月19日 | 2024年7月24日 |
股息 | 2024年3月25日 | US$8.00Special | 2024年3月18日 | — |
除息 2024年7月19日
US$1.50
Special
2024年7月19日登記 · 支付日 2024年7月24日
除息 2024年3月25日
US$8.00
Special
2024年3月18日登記
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
